Sugi Predict

Sugi Predict / Compounds / SCHEMBL721823

SCHEMBL721823

SCHEMBL721823

Nc1cc(Cl)ccc1C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.52
▸ CYP3A4 P08684 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ ALOX15 P16050 2/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ TP53 P04637 1/20 0.50
▸ MAPK1 P28482 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ FFAR1 O14842 1/20 0.41
▸ FFAR4 Q5NUL3 1/20 0.41
▸ KIF11 P52732 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ GLA P06280 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ CYP1A2 P05177 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184916 0.82 FFAR4 (0.53) TSHRCYP3A4ALDH1A1SMN1; SMN2ALOX15
SCHEMBL29365746 0.82 FFAR4 (0.53) TSHRCYP3A4ALDH1A1SMN1; SMN2ALOX15
Hydrochloric Acid SCHEMBL4377516 0.80 FFAR4 (0.51) TSHRCYP3A4ALDH1A1SMN1; SMN2ALOX15
Fluoride SCHEMBL10888732 0.80 FFAR4 (0.51) TSHRCYP3A4ALDH1A1SMN1; SMN2ALOX15
SCHEMBL5903300 0.79 AR (0.56) ALDH1A1SMN1; SMN2HPGDFFAR1FFAR4
SCHEMBL3789153 0.78 CYP3A4 (0.52) TSHRCYP3A4SMN1; SMN2TDP1TP53
SCHEMBL21507817 0.78 MAP4K4 (0.47) CYP3A4FFAR1FFAR4KIF11ACHE
SCHEMBL3793590 0.77 CYP3A4 (0.52) TSHRCYP3A4ALDH1A1SMN1; SMN2ALOX15
SCHEMBL711538 0.76 TSHR (0.60) TSHRALDH1A1SMN1; SMN2ALOX15TDP1
SCHEMBL29460325 0.76 TSHR (0.60) TSHRALDH1A1SMN1; SMN2ALOX15TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 — — US disclosed
US-12441755-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2025-10-14 — — US disclosed
US-20250304582-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2025-10-02 — — US disclosed
US-12275719-B2 Small molecule inhibitors of galectin-3 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-15 — — US disclosed
US-12269819-B2 Small molecule inhibitors of Galectin-3 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-08 — — US disclosed
EP-3498693-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2024-10-30 — — EP disclosed
US-20240309038-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2024-09-19 — — US disclosed
WO-2024149389-A1 SUBSTITUTED BRIDGE RING INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 苏州泽璟生物制药股份有限公司 2024-07-18 — — WO disclosed
EP-3947407-B1 SMALL MOLECULE INHIBITORS OF GALECTIN-3 BRISTOL MYERS SQUIBB CO (US) 2024-06-12 — — EP disclosed
CN-114728917-B Oxamide derivative, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-12-08 — — CN disclosed
US-5304554-A Intercalators of DNA, inhibit replication of retroviruses EMORY UNIVERSITY (US) 1994-04-19 — — US disclosed
US-4913728-A HERBICIDES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-04-03 — — US disclosed
US-4731450-A Process for perfluoroalkylation of aromatic derivatives RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1988-03-15 — — US disclosed
EP-0152310-B1 PROCESS FOR THE PREPARATION OF TRIFLUOROMETHYL ANILINES RHONE-POULENC CHIMIE (FR) 1987-07-22 — — EP disclosed
EP-0152310-A1 Process for the preparation of trifluoromethyl anilines RHONE-POULENC CHIMIE (FR) 1985-08-21 — — EP disclosed
EP-0109624-A2 Process for producing shaped articles made from polyurethane-polyurea which may be cellular BASF Aktiengesellschaft (DE) 1984-05-30 — — EP disclosed
EP-0082163-A1 ELECTROSTATIC, MAGNETIC DEVELOPERS, PREPARATION AND UTILIZATIONS THEREOF SUBLIGRAPHICS S.A. (CH) 1983-06-29 — — EP disclosed
WO-1983000235-A1 ELECTROSTATIC, MAGNETIC DEVELOPERS, PREPARATION AND UTILIZATIONS THEREOF HENDRIKS, DIETER 1983-01-20 — — WO disclosed
US-4313872-A MONDAZO AND DISAZO DYES CASSELLA AKTIENGESELLSCHAFT (DE) 1982-02-02 — — US disclosed
US-3932662-A ANTHELMINTICS, PYRUVOYL CHLORIDE PHENYLHYDRAZONES THE UPJOHN COMPANY (US) 1976-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 TSHR 1115/4885CYP3A4 3424/4885ALDH1A1 4260/4885
US-12275719-B2 Small molecule inhibitors of galectin-3 LGALS3, LGALS1, LGALS3BP TSHR 1382/4885CYP3A4 4137/4885ALDH1A1 2839/4885
US-12441755-B2 Galactoside inhibitor of galectins LGALS1, LGALS3, LGALS2 TSHR 1602/4885CYP3A4 2822/4885ALDH1A1 1171/4885
US-20250304582-A1 Bicyclic Ureas As Kinase Inhibitors JAK2, UCK2, ULK2 TSHR 2233/4885CYP3A4 3712/4885ALDH1A1 3820/4885
US-20240309038-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS LGALS3, LGALS1, LGALS3BP TSHR 980/4885CYP3A4 3689/4885ALDH1A1 2401/4885
US-12269819-B2 Small molecule inhibitors of Galectin-3 LGALS3, LGALS3BP, LGALS1 TSHR 1479/4885CYP3A4 4118/4885ALDH1A1 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback